<DOC>
	<DOC>NCT02718144</DOC>
	<brief_summary>This is a multi-center, open-label, phase I/IIa trial, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of estetrol for the treatment of patients with advanced breast cancer. After completing phase I part of the study (i.e. 4 weeks of treatment), patients will receive further treatment for 8 weeks at their individual phase I dose level (phase IIa part of the study).</brief_summary>
	<brief_title>Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal women with ERpositive and HER2negative locally advanced and/or metastatic breast cancer, who progressed on standard therapies or for whom standard therapies are intolerant; Patients should have experienced a natural or surgical menopause at least 5 years ago; Failure of antiestrogen treatment with tamoxifen and aromatase inhibitor(s) due to the development of resistance or unacceptable side effects with this treatment; No undiagnosed vaginal bleeding; No treatment with fulvestrant within 6 months of start of treatment; Life expectancy at least 6 months; Tumour assessment (CT scan) within 28 days before the start of the E4 treatment; Body mass index (BMI) between (≥) 18 and (≤) 35 kg/m2; Able to swallow an oral medication; Acceptable values of hematological parameters, liver and kidney function and calcium levels; Reasonable physical and mental health as judged by the investigator and determined by physical examination, clinical laboratory assessments and vital signs; Willing to give informed consent in writing. Uncontrolled nausea, vomiting, or diarrhea; History of venous or arterial thromboembolic disease or a known defect in the blood coagulation system; Uncontrolled hypertension, i.e. systolic blood pressure 160 mmHg and/or diastolic blood pressure 100 mmHg in the last 6 months with or without medication; Diabetes mellitus with poor glycaemic control in the last 6 months (HbA1c above 7.5%); Any other serious disease including systemic lupus erythematosus and untreated cholelithiasis; Smoking &gt;10 cigarettes/day; Use of any other cancer therapy including radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, chemotherapy, or use of other investigational agents at the start of treatment.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>dose-escalation</keyword>
	<keyword>safety</keyword>
	<keyword>dose-limiting toxicity</keyword>
</DOC>